GLP-1 Drugs in India 2026 — Pricing, Brands & Evidence
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medicines that work by mimicking a hormone naturally released after meals. By activating GLP-1 receptors in the pancreas, brain, and gut, these drugs stimulate insulin secretion, suppress appetite, and slow the rate at which food leaves the stomach.
Originally developed for Type 2 diabetes management, GLP-1 therapies have since demonstrated significant cardiovascular and metabolic benefits — driving their approval for obesity, cardiovascular risk reduction, and emerging indications including metabolic liver disease.
In India, GLP-1 access remains under 1% of the eligible population despite 142 million+ diabetics — creating one of the largest treatment gaps in global healthcare. A parallel generic wave has begun to close the pricing gap, with 25+ brands now competing on the same molecule.
Molecule Directory
Type 2 Diabetes, Obesity · Injectable, Oral
Ozempic, Wegovy, Rybelsus + 25 generics
Type 2 Diabetes, Obesity · Injectable
Mounjaro, Zepbound
Type 2 Diabetes, Obesity · Injectable
Victoza, Saxenda
Type 2 Diabetes · Injectable
Trulicity
Type 2 Diabetes · Injectable
Byetta, Bydureon
Brand Directory
Pricing Intelligence
PriceIQ tracks live medicine prices across brands, delivery formats and manufacturers in India — updated regularly from verified sources.
Clinical Evidence Snapshot
Key trial outcomes — summary only · Always refer to full publications
Semaglutide injectable reduced the risk of major adverse cardiovascular events (MACE) by 26% vs placebo in patients with Type 2 diabetes at high cardiovascular risk. 3,297 patients followed over 2 years.
Once-weekly semaglutide 2.4mg achieved 14.9% mean weight reduction vs 2.4% with placebo over 68 weeks in adults with obesity (BMI ≥30). 1,961 participants without Type 2 diabetes.
In 17,604 adults with obesity and established cardiovascular disease (no diabetes), semaglutide reduced MACE by 20% over approximately 3 years — establishing cardiovascular benefit independent of glycaemic control.
Tirzepatide 15mg achieved superior HbA1c reduction (−2.46%) and weight loss (−12.4kg) compared to semaglutide 1mg (−2.20% HbA1c, −6.2kg) over 40 weeks in Type 2 diabetes patients — demonstrating the GLP-1/GIP dual agonist advantage.
Tirzepatide 15mg produced 22.5% mean body weight reduction over 72 weeks in adults with obesity — the highest weight loss outcome reported for any approved pharmacotherapy at the time of publication.
Liraglutide reduced the composite of cardiovascular death, non-fatal MI, and non-fatal stroke by 13% vs placebo over 3.8 years in 9,340 Type 2 diabetes patients at high cardiovascular risk — the first GLP-1 to demonstrate cardiovascular benefit.
⚠ Summaries are editorial in nature and intended for informational purposes only. Findings are derived from published trial data — always refer to full peer-reviewed publications and approved product information for prescribing decisions. Trial data referenced: SUSTAIN-6, STEP 1, SELECT (semaglutide) · SURPASS-2, SURMOUNT-1 (tirzepatide) · LEADER (liraglutide).
Comparisons
Intelligence & Analysis
The Semaglutide Demand Explosion
$2.1B → $98B in 8 years. How semaglutide became the fastest-growing drug in pharmaceutical history — and what India's generic wave means for access and pricing.
Read insight →India Generic Wave — 14 Semaglutide Brands in 36 Months
Ozempic vs Wegovy — Same Molecule, Different Price
Frequently Asked
What is a GLP-1 receptor agonist?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medicines that mimic the action of the naturally occurring GLP-1 hormone. They stimulate insulin release in response to meals, suppress glucagon, slow gastric emptying, and reduce appetite — making them effective for both blood sugar control and weight management.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide as the active molecule. Ozempic is approved for Type 2 diabetes management (doses: 0.25mg–1mg weekly) while Wegovy is approved for chronic weight management (doses up to 2.4mg weekly). Wegovy uses higher doses to achieve greater weight loss outcomes.
Is oral semaglutide available in India?
Yes — Rybelsus (Novo Nordisk) and several generic oral semaglutide tablets are available in India in 3mg, 7mg, and 14mg strengths. Oral semaglutide has lower bioavailability than injectable forms and must be taken 30 minutes before the first meal with plain water only.
How much does semaglutide cost in India?
Semaglutide prices in India vary significantly across brands and delivery formats. Economy generic brands start from approximately ₹219/mg while premium branded options (Ozempic, Wegovy) can reach ₹5,660/mg — a 25× price variation for the same active molecule.
What is tirzepatide and how is it different from semaglutide?
Tirzepatide is a dual GLP-1/GIP receptor agonist (targets two hormone pathways vs semaglutide's one). Clinical trials show tirzepatide achieves greater weight loss and HbA1c reduction than semaglutide at equivalent doses. It is marketed as Mounjaro (diabetes) and Zepbound (obesity) by Eli Lilly.
Are GLP-1 drugs covered by insurance in India?
Most GLP-1 therapies are not covered under standard health insurance policies in India. Some employer-sponsored health plans may partially cover diabetes-indicated GLP-1 drugs (Ozempic, Rybelsus) but obesity indications (Wegovy) are typically excluded. Always verify with your insurer before prescribing or purchasing.
What is the cheapest GLP-1 drug available in India?
Economy generic semaglutide brands represent the most affordable GLP-1 option currently available in India. Jan Aushadhi does not yet stock GLP-1 therapies. Compare live pricing across all brands on PriceIQ for the most current data.
⚠ Content on this page is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making prescribing or treatment decisions.
Data verified May 2026 · RxIntel · rxintel.link/glp-1